Apotheca Biosciences, Inc. (CBDC) financial statements (2020 and earlier)
Company profile
| Business Address |
10901 ROOSEVELT BLVD., SAINT PETERSBURG, FL 33716 |
| State of Incorp. | NV |
| Fiscal Year End | January 31 |
| SIC | 10 - Metal Mining (benchmarking) |
| More info | Complete financial analysis Financial benchmarking |
Balance sheet (Statement of financial position) ($ in thousands)
| 4/30/2019 TTM | 1/31/2019 | 1/31/2018 | 1/31/2017 | 1/31/2016 | |||
|---|---|---|---|---|---|---|---|
| ASSETS | |||||||
| Current Assets | |||||||
| Cash, cash equivalents, and short-term investments | 3 | 0 | 3 | ||||
| Cash and cash equivalents | 3 | 0 | 3 | ||||
| Inventory, net of allowances, customer advances and progress billings | 8 | ||||||
| Inventory | 8 | ||||||
| Prepaid expense | 6 | ||||||
| Deposits current assets | 6 | ||||||
| Other undisclosed current assets | 86 | ||||||
| Total current assets: | 109 | 0 | 3 | ||||
| Noncurrent Assets | |||||||
| Property, plant and equipment | 6 | ||||||
| Total noncurrent assets: | 6 | ||||||
| TOTAL ASSETS: | 115 | 0 | 3 | ||||
| LIABILITIES AND EQUITY | |||||||
| Liabilities | |||||||
| Current Liabilities | |||||||
| Accounts payable and accrued liabilities, including: | 107 | 18 | 5 | 1 | |||
| Accounts payable | 24 | ||||||
| Accrued liabilities | 83 | ||||||
| Other undisclosed accounts payable and accrued liabilities | 18 | 5 | 1 | ||||
| Debt | 19 | 157 | |||||
| Due to related parties | 8 | 47 | 29 | 28 | |||
| Total current liabilities: | 134 | 222 | 33 | 29 | |||
| Noncurrent Liabilities | |||||||
| Other undisclosed liabilities | 798 | ||||||
| Total liabilities: | 932 | 222 | 33 | 29 | |||
| Stockholders' equity | |||||||
| Stockholders' equity attributable to parent, including: | (817) | (222) | (33) | (26) | |||
| Common stock | 118 | 50 | |||||
| Additional paid in capital | 1,504 | 17 | 38 | 27 | |||
| Accumulated deficit | (2,512) | (290) | (79) | (61) | |||
| Other undisclosed stockholders' equity attributable to parent | 74 | 8 | 8 | ||||
| Total stockholders' equity: | (817) | (222) | (33) | (26) | |||
| TOTAL LIABILITIES AND EQUITY: | 115 | 0 | 3 | ||||
Income statement (P&L) ($ in thousands)
| 4/30/2019 TTM | 1/31/2019 | 1/31/2018 | 1/31/2017 | 1/31/2016 | ||
|---|---|---|---|---|---|---|
| Gross profit: | (62) | |||||
| Operating expenses | (2,276) | (188) | (15) | (34) | ||
| Other undisclosed operating income | 62 | |||||
| Operating loss: | (2,276) | (188) | (15) | (34) | ||
| Nonoperating expense | (236) | (8) | ||||
| Loss before gain (loss) on sale of properties: | (2,512) | (196) | (15) | (34) | ||
| Other undisclosed net loss | (3) | (5) | ||||
| Net loss available to common stockholders, diluted: | (2,512) | (196) | (18) | (39) | ||
Comprehensive Income ($ in thousands)
| 4/30/2019 TTM | 1/31/2019 | 1/31/2018 | 1/31/2017 | 1/31/2016 | ||
|---|---|---|---|---|---|---|
| Net loss: | (2,512) | (196) | (18) | (39) | ||
| Comprehensive loss, net of tax, attributable to parent: | (2,512) | (196) | (18) | (39) | ||
Statements sources
The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.